HOW TO PARTNER WITH SAWAZISHA

Different doors. One shared refusal to accept neglect.

Back a portfolio moving from market entry and clinical validation to platform science and local manufacture.

Help generate the evidence and infrastructure required to move neglected problems toward care. Our intended impact is ambitious. Our claims will remain disciplined. Product-specific outcomes will be published only when the relevant bench, safety, usability and clinical evidence supports them.

30.7%

of women aged 15–49 globally were living with anaemia in 2023. (UN SDG Report / WHO estimates)

16–91%

is the reported prevalence range for dysmenorrhoea across studies. (Ju et al., 2014)

17 trials

studied perineal techniques in nearly 13,700 women—yet key outcomes remain under-reported. (Cochrane, 2024)

2 hours

is the WHO-recommended early-treatment window for eligible intubated preterm newborns with RDS. (WHO preterm infant guidance)

01

Investors

Back a portfolio moving from market entry and clinical validation to platform science and local manufacture.

02

Grant funders

Help generate the evidence and infrastructure required to move neglected problems toward care.

Pipeline Milestones

Stage Gates & Capital Opportunities

Track how each innovation advances from frontline insight to bench testing, clinical validation, and cleanroom scale.

Clinical validation

Waridi™

Perineal protection

Clinical study preparation and regulatory engagement

Target Capital Alignment:Investigational device · clinical and regulatory preparation
Prototype development

Zawadi™

Earlier iron insight

Prototype build, calibration and clinical feasibility work

Target Capital Alignment:Grant-backed platform · device and algorithm development
Market-entry preparation

WarmEase™

Dysmenorrhoea relief

Product verification, manufacturing readiness and market introduction

Target Capital Alignment:Consumer health · preparing for market introduction
Grant-funded research

Vaginal Formulations

Platform science

Formulation optimisation and preclinical characterisation

Target Capital Alignment:GCA-016 · formulation research and preclinical characterisation
Early feasibility

SawaSurf™

Neonatal respiratory care

Feasibility, process development and preclinical planning

Target Capital Alignment:Process development · preclinical planning
Institutional Engagement

Request Diligence Access or Schedule an Introduction

Direct access to our leadership team, financial models, clinical protocols, and stage-gate progression dossiers.

Our Standard

Affordable for Kirehe. Acceptable anywhere else. We build for world-class quality, rigorous evidence, and real affordability at the same time.

All non-public disclosures are governed under standard mutual confidentiality agreements.